Reverse Effect of Selenium Chiston on Multidrug Resistance in Human Leukemia Cell Line K562/ADM
|更新时间:2024-01-04
|
Reverse Effect of Selenium Chiston on Multidrug Resistance in Human Leukemia Cell Line K562/ADM
Chinese Journal of Experimental Traditional Medical FormulaeVol. 18, Issue 12, Pages: 179-182(2012)
作者机构:
作者简介:
基金信息:
DOI:
CLC:
Published:2012
稿件说明:
移动端阅览
DENG Shou-heng, PAN Dong-feng, LI Fang, et al. Reverse Effect of Selenium Chiston on Multidrug Resistance in Human Leukemia Cell Line K562/ADM[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(12): 179-182.
DOI:
DENG Shou-heng, PAN Dong-feng, LI Fang, et al. Reverse Effect of Selenium Chiston on Multidrug Resistance in Human Leukemia Cell Line K562/ADM[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(12): 179-182.DOI:
Reverse Effect of Selenium Chiston on Multidrug Resistance in Human Leukemia Cell Line K562/ADM
Objective: To study the influence of selenium chiston (SC) on mdr-1 gene and P-glycprotein(P-gp) expression in multidrug resistance human leukemia cell line K562/ adriamycin(ADM) in vitro. Method: After treated with 100
200 mg·L-1 SC for 24 h. The expression level of P-gp in K562/ADM was determined by western blot and transcription of mdr-1 gene was detected by semi-quantitative RT-PCR. The intracellular ADM concentration was tested by HPLC. The proliferation of K562/ADM cell line was determinde by MTT. Result: The relative efficiency of K562/ADM to ADM and the intracellular accumulation of ADM increased after SC treatment and the effect of 200 mg·L-1 SC was more obvious than that of 100 mg·L-1 SC(P<0.01);SC could inhibit the expression of mdr-1/P-gp according to results of semi-quantitative RT-PCR and Western blot(P<0.01)
the down-regulating rate on mdr-1/P-gp was(40.87±3.19)%and(35.08±0.09)% in 100 mg·L-1 SC group
(78.24±3.42)%and(79.61±0.23)% in 200 mg·L-1 SC group. Conclusion: SC could obviously inhibite the P-gp protein and mdr-1 gene expression and could effectively restore the sensitivity of K562/ADM cells to conventional chemotherapeutic.